Physician profile
Catherine Mckee
NPI 1134585532
$1,716.38
in general payments reported to CMS, 2019-2025
25 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $181 · 2023: $354 · 2024: $296 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.44 | 2021 | |
| Novo Nordisk INC | $180.70 | 2021 | |
| Abbvie INC. | $176.57 | 2021-2022 | |
| Eisai INC. | $128.00 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $109.02 | 2023-2024 | Rexulti, Nuedexta |
| Mylan Specialty L.P. | $99.31 | 2022-2023 | Yupelri |
| Glaxosmithkline, LLC. | $87.22 | 2023-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $75.21 | 2023-2024 | Amyvid, Trulicity, Mounjaro |
| Dynavax Technologies Corporation | $73.28 | 2023-2025 | Heplisav-B |
| Edwards Lifesciences Corporation | $72.09 | 2021-2024 | Sapien 3 Ultra Resilia |
| Teva Pharmaceuticals USA, INC. | $53.82 | 2023 | Austedo Xr |
| Intuitive Surgical, INC. | $44.81 | 2023 | |
| Organon LLC | $41.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $40.14 | 2024-2025 | |
| Soleno Therapeutics, INC. | $37.17 | 2025 | Vykat Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $32.57 | 2022-2024 | Crysvita |
| Exact Sciences Corporation | $32.23 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $31.55 | 2021 | |
| Merck Sharp & Dohme LLC | $29.87 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Recor Medical INC | $27.36 | 2024 | Paradise Renal Denervation System |
| Pfizer INC. | $20.62 | 2025 | |
| Lundbeck LLC | $14.81 | 2022 | |
| W. L. Gore & Associates, INC. | $14.80 | 2021 | |
| Medtronic, INC. | $14.79 | 2025 | Inceptiv |
| Vbi Vaccine (Delaware) INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.